In October, high-profile U.K. fund manager Neil Woodford advocated for a four-way breakup of GlaxoSmithKline, a company he said could unlock "significant shareholder value" by splitting apart. And he hasn't quit championing that idea.
Merck and GlaxoSmithKline have spent years working to build the market for their HPV vaccines, and a new study may demonstrate one factor that has hindered their efforts.
2016 is the year that GlaxoSmithKline is supposed to start to show the results of CEO Andrew Witty's turnaround efforts. Well 2016 is here and Witty is expected to show up at the JP Morgan Healthcare Conference next week with plans he hopes will convince investors that his efforts to remake the British pharma giant have not been in vain.
GlaxoSmithKline has a new drug that's tailored for patients with a specific type of severe asthma. But according to a nonprofit body that evaluates drugs' prices against their clinical effectiveness, it costs far, far too much.
It wasn't all that long ago that GlaxoSmithKline was considering a spinoff for its HIV drugs division, ViiV Healthcare. Now, though, the company is hanging on tight to that business--and building it up, too.
In March, GlaxoSmithKline and Novartis completed their $7.1 billion asset swap that was nearly a year in the making. The deal saw the British pharma bolster its vaccine business as it traded away its oncology unit for Novartis' vaccines business. Now, Glaxo is officially announcing the launch of GSKDirect, a new e-commerce platform that simplifies the way customers order vaccines and pharmaceutical products from the company.
Bristol-Myers Squibb is getting out of HIV R&D;, selling its pipeline to the GlaxoSmithKline-controlled ViiV Healthcare in a transaction worth as much as $3 billion.
The FDA has lifted the final layer of safety measures on the GlaxoSmithKline diabetes drug Avandia, 8 years after researchers flagged an apparent increase in the risk of heart attack, and at least three years too late to make a difference in sales. The safety questions drove Avandia revenues down from a peak of $3 billion before the controversy to $183 million in 2011, just before generics hit the market.
Partners GlaxoSmithKline and Johnson & Johnson posted positive Phase III results for an injected treatment for rheumatoid arthritis, plotting to submit the therapy for global approvals next year.
One month after a European safety review raised no issues with the blockbuster-to-be HPV vaccine Gardasil 9, Merck received another boost for its jab this week.